McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted extensively in a January 8, 2016 edition of Bloomberg BNA’s Life Sciences Law & Industry Report in an article entitled, “Biosimilars, Digital Health, Patents Called Top Issues for 2016.” Bloomberg BNA’s Life Sciences Law & Industry Report asked noted life sciences attorneys for their top issues for 2016. While concerns about patent eligibility for natural and diagnostic products and other patent related issues took up six of the top 10 spots, the attorneys gave high importance to the potential impact of approvals of more biosimilars, the growth of integrated digital health and continuing megadeals and partnering. View the article